Olmesartan Medoxomil and Rosuvastatin Tablets 20/10 mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Hanpoong Pharmaceutical Co., Ltd.
MFDS item code 202003980 · Approved 2020.05.28
This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension, improvement of dyslipidemia, suppression of atherosclerosis progression and cardiovascular disease risk
This medication is used for patients who require concomitant treatment with olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil is primarily used for the treatment of essential hypertension and is effective in lowering blood pressure. Rosuvastatin is used as an adjunct to dietary treatment for lipid disorders, such as hypercholesterolemia and mixed dyslipidemia. It also helps to lower total cholesterol and LDL-cholesterol in patients at high risk for cardiovascular diseases, slowing the progression of atherosclerosis and reducing the risks associated with stroke, myocardial infarction, and arterial revascularization. Therefore, this medication is used to manage hypertension and dyslipidemia simultaneously, reducing the risk of cardiovascular diseases and improving health.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.
Safety and efficacy have not been established in children under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; hence, it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to individuals with a known allergy to this medication or its components, pregnant or potentially pregnant women, breastfeeding mothers, patients undergoing renal dialysis, those with severe renal impairment, patients with severe liver dysfunction, those with biliary obstruction, and patients with muscle disorders. Caution should be taken with patients who have reduced blood volume or low sodium levels, as hypotension may occur, and their condition should be closely monitored. Patients with severe congestive heart failure, who rely on the renin-angiotensin-aldosterone system for kidney function, should be administered this medication with caution because changes in renal function may occur. Patients at risk of hyperkalemia should have their serum potassium levels regularly monitored. Patients with aortic or mitral stenosis, obstruction, and hypertrophic cardiomyopathy may experience exacerbated symptoms due to the blood pressure-lowering effect. This medication may cause muscle-related side effects such as myalgia, myopathy, and rarely, rhabdomyolysis; therefore, patients should consult a physician if they experience severe muscle pain or weakness. Those with a history of alcohol consumption or liver disease should regularly undergo liver function tests as liver dysfunction may occur. During treatment, caution is advised regarding activities such as driving or operating machinery due to the risk of dizziness and other side effects. Additionally, this medication may interact with other drugs, so patients should inform healthcare professionals of any other medications they are taking. Women who are pregnant or planning to become pregnant must consult with healthcare professionals regarding appropriate contraceptive methods, and those who are breastfeeding should also avoid using this medication. Elderly patients or those with impaired renal function require dosage adjustments and monitoring for side effects. In the event of overdose, symptoms such as hypotension and palpitations may occur, so patients should report any abnormal symptoms immediately to their healthcare providers. The safety and efficacy of this medication have not been established in children; therefore, it should not be used in pediatric populations.
ALT elevation, AST elevation, increased serum creatinine, reduced creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, thoracic pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, vascular edema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), headache, palpitations, increased blood pressure, lumbago, increase in serum creatinine, diarrhea, chest pain, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including vascular edema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is advised to avoid extreme temperatures, storing it at room temperature between 1°C and 30°C.
White or light yellow, round film-coated tablets
30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Hanpoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.